Import Paclieva 300mg Injection from India to USA – Ernest Oncology

Comprehensive Guide to Paclieva 300mg Injection: Global Export & Distribution by Ernest Oncology

At Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.), we are an internationally recognized exporter, bulk supplier, and distributor of critical oncology formulations. We specialize in the secure, compliant, and efficient supply of Paclieva 300mg Injection to healthcare providers, hospitals, and pharmaceutical distributors worldwide, with targeted delivery networks in the USA, UK, Australia, and South Africa.

This comprehensive guide covers the medical profile, mechanisms, uses, and an extensive list of SEO keywords designed to boost the online visibility of B2B pharmaceutical suppliers.

1. What is Paclieva 300mg Injection?

Paclieva 300mg Injection (containing Paclitaxel 300mg per 50ml) is a potent, frontline chemotherapy medication that belongs to the taxane class. It acts as an antimicrotubule agent designed to inhibit cell division and induce cell death (apoptosis) in rapidly dividing malignant cells.

Key Product Details

• Composition: Paclitaxel (300 mg / 50 mL vial).

• Therapeutic Class: Anti-neoplastic agent / Chemotherapeutic medication.

• Mechanism Class: Antimicrotubular inhibitor.

• Dosage Form: Concentrate for solution for intravenous (IV) infusion.

2. Mechanism of Action

Paclieva 300mg targets the structural framework of cancer cells through the following steps:

• Microtubule Stabilization: Microtubules are essential for cell division. Paclitaxel binds to tubulin, preventing the breakdown of microtubules.

• Mitotic Arrest: By preventing the microtubules from functioning correctly, the cell is locked in the G2/M phase of the cell cycle.

• Apoptosis: The inability of the cell to complete division triggers apoptosis, selectively killing malignant cells and halting tumor growth.

3. Therapeutic Indications and Uses

Paclieva 300mg is indicated for the treatment of several solid tumors, often administered as part of a combination regimen or as a standalone agent:

• Breast Cancer: Used for both early-stage post-surgery treatment and metastatic or node-positive breast cancer.

• Pancreatic Cancer: Acts to control disease progression and relieves symptoms such as lack of appetite and unexplained weight loss.

• Non-Small Cell Lung Cancer (NSCLC): Administered alongside other platinum-based agents for advanced lung tumors.

• Ovarian Cancer: Used in advanced stages or following initial surgery.

• AIDS-Related Kaposi's Sarcoma: Used when standard systemic treatments have failed.

4. Administration and Storage

Administration

• Route: Administered exclusively via intravenous (IV) infusion under the supervision of an experienced oncologist or healthcare professional.

• Protocol: Usually given over a 1 to 3-hour period every three weeks, depending on the protocol.

• Pre-medication: Patients are typically pre-medicated with corticosteroids or antihistamines to prevent severe hypersensitivity reactions.

Storage and Handling

• Storage Temperature: Store below 30°C or as specified on the package. Do not freeze.

• Protect the vial from light and keep out of reach of children.

5. Potential Side Effects and Safety Warnings

• Common Side Effects: Nausea, vomiting, diarrhea, hair loss, fatigue, muscle/joint pain, and peripheral neuropathy (tingling or numbness in hands and feet).

• Serious Risks: Myelosuppression (anemia, neutropenia, thrombocytopenia), and severe hypersensitivity reactions (swelling of the face, throat, and lips; difficulty breathing).

• Contraindications: Highly unsafe during pregnancy and lactation. The medication contains alcohol, which may be of concern for patients with alcohol-related disorders or liver issues. Regular blood monitoring is required.